Lead asset
GE07 is the current external opportunity: a PDE7 inhibitor programme available for licensing, acquisition or co-development
FOCUSED RARE DISEASE PORTFOLIO
Programme | Indication | Target | AI discovery | Preclinical | IND-enabling | Status |
|---|---|---|---|---|---|---|
GE07 | Fragile X syndrome | PDE7 | Complete | Advanced | Planned | Available for partnering |
Discovery programmes | Rare neurodevelopment | Undisclosed | Planned | Planned | — | Internal |
